Business
SINTX TECHNOLOGIES ANNOUNCES APPOINTMENT OF MARK I. FROIMSON, M.D., TO ITS BOARD OF DIRECTORS
SALT LAKE CITY, UT, March 02, 2020 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ: SINT) (“SINTX” or the “Company”), an original equipment manufacturer
About this update from Sintx Technologies, Inc.
[{"type":"text","content":"SALT LAKE CITY, UT, March 02, 2020 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ: SINT) (“SINTX” or the “Company”), an original equipment manufacturer (OEM) ceramics company focused on silicon nitride applications, today announced the appointment of Mark I. Froimson, M.D. to its board of directors.\n Dr. Froimson is currently a Principal at Riverside Health Advisors, a consulting company that provides strategic advice and services to health care executive leaders. Dr. Froimson served as past President of the American Association of Hip and Knee Surgeons, and as the Executive Vice President and Chief Clinical Officer of Trinity Health, a national non-profit Catholic healthcare system comprising 93 hospitals in 22 states. Prior to the position at Trinity Health, Dr. Froimson was President and CEO of Euclid Hospital, a part of the Cleveland Clinic system. Dr. Froimson served as a staff surgeon in the Department of Orthopedic Surgery at the Cleveland Clinic for over 16 years, during which time he held many leadership positions including Medical Staff President, Vice Chair of the Orthopedic and Rheumatologic Institute, and member of the Board of Governors and Board of Trustees. Dr. Froimson serves on the Board of Directors of Pacira Biosciences, Inc., a publicly traded company on the NASDAQ Stock Market, and on the national Board of Directors of the Arthritis Foundation. “Mark’s clinical expertise, leadership, and proven track record of driving medical innovation, and extensive contacts in the orthopaedic medical device space will complement SINTX’s expansion of its technology platform beyond spine, toward arthroplasty applications,” said Dr. Sonny Bal, chairman and chief executive officer of SINTX. “We welcome Mark and look forward to his contributions to SINTX.” “SINTX’s proprietary technology, and unsurpassed research, promise to unleash the potential of silicon nitride for additional medical and healthcare applications. Given the compelling evidence of the superior antimicrobial properties of this material, there promises to be an increased role in procedures that would benefit from a reduction in rates of surgical site infection,” Froimson noted. “I am thrilled to be joining this industry leading team that is poised to make significant inroads in an industry looking for meaningful innovations that can benefit patients.” D...